Activation of NF-κB within myeloma cells occurs through a range of mechanisms, including the inactivation of pathway suppressors through gene deletions and/or mutations, and pathway hyperactivity due to translocations and copy number gains [78, 79]. The gene discussed is NFKB1; the disease is plasma cell myeloma.